Halozyme Therapeutics (HALO) Total Debt (2012 - 2026)

Halozyme Therapeutics (HALO) has 15 years of Total Debt data on file, last reported at $2.1 billion in Q1 2026.

• On a quarterly basis, Total Debt rose 42.27% year-over-year to $2.1 billion in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 42.27% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, up 42.29% from the prior year.
• Total Debt for Q1 2026 stood at $2.1 billion, roughly flat from $2.1 billion in the prior quarter.
• Over the last five years, Total Debt for HALO reached as high as $2.1 billion in Q1 2026 and fell as low as $877.6 million in Q1 2022.
• Historically, Total Debt has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2024.
• Across the five-year window, Total Debt surged 73.32% in 2022 and slipped 1.33% in 2023, its largest moves.
• Year by year, Total Debt stood at $1.5 billion in 2022, then decreased by 1.33% to $1.5 billion in 2023, then gained by 0.44% to $1.5 billion in 2024, then jumped by 42.29% to $2.1 billion in 2025, then gained by 0.09% to $2.1 billion in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $2.1 billion in Q1 2026, $2.1 billion in Q4 2025, and $1.5 billion in Q3 2025.